Cellular Mechanisms of Psoriasis Pathogenesis: A Systemic Review

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Naldi L. Epidemiology of major chronic inflammatory immune-related skin diseases in 2019. Expert Rev Clin Immunol. 2020;16(2):155–166. doi:10.1080/1744666X.2020.1719833
   PubMed Web of Science ®Google Scholar
• Machado-Pinto J, Diniz Mdos S, Bavoso NC. Psoriasis: new comorbidities. An Bras Dermatol. 2016;91(1):8–14. doi:10.1590/abd1806-4841.20164169
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Ferdinando LB, Fukumoto PK, Sanches S, Fabricio LHZ, Skare TL. Metabolic syndrome and psoriasis: a study in 97 patients. Rev Assoc Med Bras. 2018;64(4):368–373. doi:10.1590/1806-9282.64.04.368
   PubMed Web of Science ®Google Scholar
• Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37(5):2017–2033. doi:10.1007/s12325-020-01346-6
   PubMed Web of Science ®Google Scholar
• Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int. 2018;2018:3140682. doi:10.1155/2018/3140682
   PubMed Web of Science ®Google Scholar
• Damiani G, Radaeli A, Olivini A, Calvara-Pinton P, Malerba M. Increased airway inflammation in patients with psoriasis. Br J Dermatol. 2016;175(4):797–799. doi:10.1111/bjd.14546
   PubMed Web of Science ®Google Scholar
• Furue M, Kadono T. “Inflammatory skin march” in atopic dermatitis and psoriasis. Inflamm Res. 2017;66(10):833–842. doi:10.1007/s00011-017-1065-z
   PubMed Web of Science ®Google Scholar
• Rousset L, Halioua B. Stress and psoriasis. Int J Dermatol. 2018;57(10):1165–1172. doi:10.1111/ijd.14032
   PubMed Web of Science ®Google Scholar
• Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a UK population-based cohort study. Br J Dermatol. 2017;176(3):650–658. doi:10.1111/bjd.15021
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Uppala R, Tsoi LC, Harms PW, et al. “Autoinflammatory psoriasis”-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307–317. doi:10.1038/s41423-020-0519-3
   PubMed Web of Science ®Google Scholar
• Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264–272. doi:10.1111/1346-8138.14139
   PubMed Web of Science ®Google Scholar
• Barker JNWN, Griffiths CEM, Nickoloff BJ, Mitra RS, Dixit VM, Nickoloff BJ. Keratinocytes as initiators of inflammation. Lancet. 1991;337(8735):211–214. doi:10.1016/0140-6736(91)92168-2
   PubMed Web of Science ®Google Scholar
• Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9(10):679–691. doi:10.1038/nri2622
   PubMed Web of Science ®Google Scholar
• Michael M, Amel T, Evelyn G, et al. Self-antigen presentation by keratinocytes in the inflamed adult skin modulates T-cell auto-reactivity. J Invest Dermatol. 2015;135(8):1996–2004. doi:10.1038/jid.2015.130
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-3
   PubMed Web of Science ®Google Scholar
• Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5(1):5621. doi:10.1038/ncomms6621
   PubMed Web of Science ®Google Scholar
• Kim TG, Kim SH, Lee MG. The origin of skin dendritic cell network and its role in psoriasis. Int J Mol Sci. 2017;19(1):42. doi:10.3390/ijms19010042
   PubMed Web of Science ®Google Scholar
• Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14(4):286–292. doi:10.1016/j.autrev.2014.11.012
   PubMed Web of Science ®Google Scholar
• Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302–309. doi:10.1038/cmi.2012.15
   PubMed Web of Science ®Google Scholar
• Benhadou F, Glitzner E, Brisebarre A, et al. Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease. Sci Adv. 2020;6(2):eaax5849. doi:10.1126/sciadv.aax5849
   PubMed Web of Science ®Google Scholar
• Xu M, Lu H, Lee YH, et al. An interleukin-25-mediated autoregulatory circuit in keratinocytes plays a pivotal role in psoriatic skin inflammation. Immunity. 2018;48(4):787–798.e784. doi:10.1016/j.immuni.2018.03.019
   PubMed Web of Science ®Google Scholar
• Zeng F, Chen H, Chen L, et al. An autocrine circuit of IL-33 in keratinocytes is involved in the progression of psoriasis. J Invest Dermatol. 2021;141(3):596–606.e597. doi:10.1016/j.jid.2020.07.027
   PubMed Web of Science ®Google Scholar
• Wang MC, Zhang SS, Zheng GX, et al. Gain-of-function mutation of card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49(1):66–+. doi:10.1016/j.immuni.2018.05.012
   PubMed Web of Science ®Google Scholar
• Moos S, Mohebiany AN, Waisman A, Kurschus FC. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. J Invest Dermatol. 2019;139(5):1110–1117. doi:10.1016/j.jid.2019.01.006
   PubMed Web of Science ®Google Scholar
• Lou F, Sun Y, Xu Z, et al. Excessive polyamine generation in keratinocytes promotes self-RNA sensing by dendritic cells in psoriasis. Immunity. 2020;53(1):204–216 e210. doi:10.1016/j.immuni.2020.06.004
   PubMed Web of Science ®Google Scholar
• Chen HL, Lo CH, Huang CC, et al. Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis. J Clin Invest. 2021;131(1). doi:10.1172/JCI130740
   Web of Science ®Google Scholar
• Jiang M, Fang H, Shao S, et al. Keratinocyte exosomes activate neutrophils and enhance skin inflammation in psoriasis. FASEB J. 2019;33(12):13241–13253. doi:10.1096/fj.201900642R
   PubMed Web of Science ®Google Scholar
• Huang C, Zhong W, Ren X, et al. MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes. Cell Death Dis. 2021;12(11):963. doi:10.1038/s41419-021-04230-5
   PubMed Web of Science ®Google Scholar
• Michel G, Wei C, Yong-Jun L. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8(8):594. doi:10.1038/nri2358
   PubMed Web of Science ®Google Scholar
• Nestle FO, Curdin C, Adrian TK, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135–143. doi:10.1084/jem.20050500
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Günther S, Moderer M, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol. 2002;119(5):1096–1102. doi:10.1046/j.1523-1747.2002.19515.x
   PubMed Web of Science ®Google Scholar
• Michel G, Curdin C, Michael G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140(12):1490. doi:10.1001/archderm.140.12.1490
   PubMedGoogle Scholar
• Schmid P, Itin P, Cox D, Mcmaster GK, Horisberger MA. The type I interferon system is locally activated in psoriatic lesions. J Interferon Res. 1994;14(5):229–234. doi:10.1089/jir.1994.14.229
   PubMedGoogle Scholar
• Walter A, Schäfer M, Cecconi V, et al. Aldara activates TLR7-independent immune defence. Nat Commun. 2013;4(3):1560. doi:10.1038/ncomms2566
   PubMedGoogle Scholar
• Cristina A, Claudia S, Sabatino P, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med. 2009;206(1):249. doi:10.1084/jem.20080129
   PubMed Web of Science ®Google Scholar
• Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983–1994. doi:10.1084/jem.20090480
   PubMed Web of Science ®Google Scholar
• Roberto L, Josh G, Valeria F, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–569. doi:10.1038/nature06116
   PubMed Web of Science ®Google Scholar
• Shin M, Kenshi Y, Beda M, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012;132(1):135–143. doi:10.1038/jid.2011.259
   PubMed Web of Science ®Google Scholar
• Yin Q, Sun L, Cai X, et al. Lidocaine ameliorates psoriasis by obstructing pathogenic CGRP signaling‒mediated sensory neuron‒dendritic cell communication. J Invest Dermatol. 2022;142(8):2173–2183.e2176. doi:10.1016/j.jid.2022.01.002
   PubMed Web of Science ®Google Scholar
• Zaba LC, Irma C, Patricia G, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–3194. doi:10.1084/jem.20071094
   PubMed Web of Science ®Google Scholar
• Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest. 1994;94(1):202–209. doi:10.1172/JCI117308
   PubMed Web of Science ®Google Scholar
• Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23. doi:10.1016/j.det.2014.09.002
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. doi:10.1038/nrdp.2016.82
   PubMed Web of Science ®Google Scholar
• Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol. 2009;129(2):302–308. doi:10.1038/jid.2008.225
   PubMed Web of Science ®Google Scholar
• Zaba LC, Judilyn FD, Narat John E, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129(1):79. doi:10.1038/jid.2008.194
   PubMed Web of Science ®Google Scholar
• Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci. 2005;102(52):19057–19062. doi:10.1073/pnas.0509736102
   PubMed Web of Science ®Google Scholar
• Frank W, Edmund L, Lowes MA, et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. Digest World Core Med J. 2006;126(7):1590–1599.
   Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. doi:10.1084/jem.20030451
   PubMed Web of Science ®Google Scholar
• Sa SM, Valdez PA, Jianfeng W, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178(4):2229. doi:10.4049/jimmunol.178.4.2229
   PubMed Web of Science ®Google Scholar
• Gamze P, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908–1915. doi:10.4049/jimmunol.176.3.1908
   PubMed Web of Science ®Google Scholar
• Bing S. T Helper Cell Differentiation and Their Function. Springer; 2014.
   Google Scholar
• Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102(2):145–149. doi:10.1111/1523-1747.ep12371752
   PubMed Web of Science ®Google Scholar
• Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (Cytotoxic T Lymphocyte) and TH1 effector populations: 1 a type 1 differentiation bias is. J Invest Dermatol. 1999;113(5):752–759. doi:10.1046/j.1523-1747.1999.00749.x
   PubMed Web of Science ®Google Scholar
• Kenan A, Okan T, Sevim A, et al. Effects of malassezia yeasts on serum Th1 and Th2 cytokines in patients with guttate psoriasis. Int J Dermatol. 2013;52(1):46–52. doi:10.1111/j.1365-4632.2011.05280.x
   PubMed Web of Science ®Google Scholar
• Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol. 1998;111(6):1072–1078. doi:10.1046/j.1523-1747.1998.00419.x
   PubMed Web of Science ®Google Scholar
• Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101(5):701. doi:10.1111/1523-1747.ep12371679
   PubMed Web of Science ®Google Scholar
• Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273–279.
   PubMed Web of Science ®Google Scholar
• Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383. doi:10.1038/jid.2009.399
   PubMed Web of Science ®Google Scholar
• Ilona K, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181(7):4733. doi:10.4049/jimmunol.181.7.4733
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi:10.1016/j.jaci.2017.07.004
   PubMed Web of Science ®Google Scholar
• Dinarello CA. IL-18: a TH1 -inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103(1):11–24. doi:10.1016/S0091-6749(99)70518-X
   PubMed Web of Science ®Google Scholar
• Chung Y, Chang SH, Martinez GJ, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009;30(4):576–587. doi:10.1016/j.immuni.2009.02.007
   PubMed Web of Science ®Google Scholar
• Lin Y, Xue K, Li Q, et al. Cyclin-dependent kinase 7 promotes Th17/Th1 cell differentiation in psoriasis by modulating glycolytic metabolism. J Invest Dermatol. 2021;141(11):2656–2667.e2611. doi:10.1016/j.jid.2021.04.018
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133. doi:10.1016/j.cell.2006.07.035
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28(1):29–39. doi:10.1016/j.immuni.2007.11.016
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600. doi:10.1038/nri3707
   PubMed Web of Science ®Google Scholar
• Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. 2015;43(6):1040–1051. doi:10.1016/j.immuni.2015.12.003
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836–5845. doi:10.4049/jimmunol.0802999
   PubMed Web of Science ®Google Scholar
• Chan JR, Wendy B, Erin M, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–2587. doi:10.1084/jem.20060244
   PubMed Web of Science ®Google Scholar
• Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res. 2010;302(7):499–505. doi:10.1007/s00403-010-1033-8
   PubMedGoogle Scholar
• Carlo C, Rachel C, Montserrat A, et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood. 2008;112(9):3696. doi:10.1182/blood-2008-05-155408
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. doi:10.1056/NEJMoa1512711
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2). Lancet. 2008;371(9625):1675–1684. doi:10.1016/S0140-6736(08)60726-6
   PubMed Web of Science ®Google Scholar
• Chiara O, Francesca N, Chiara B, Ornella DP, Giampiero G, Andrea C. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol. 2010;36(1):118–128.
   Google Scholar
• Kastelan M, Massari L, Gruber F, et al. Perforin expression is upregulated in the epidermis of psoriatic lesions. Br J Dermatol. 2004;151(4):831–836. doi:10.1111/j.1365-2133.2004.06168.x
   PubMed Web of Science ®Google Scholar
• Büchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol. 2007;25(6):616–624. doi:10.1016/j.clindermatol.2007.08.016
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the Phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi:10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Ekman A.K., Bivik Eding C., Rundquist I., et al. IL-17 and IL-22 Promote Keratinocyte Stemness in the Germinative Compartment in Psoriasis. The Journal of investigative dermatology. 2019;139 7 :1564–1573.e8. doi:10.1016/j.jid.2019.01.014
   PubMed Web of Science ®Google Scholar
• Ekman AK, Bivik Eding C, Rundquist I, Enerbäck C. IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis. J Invest Dermatol. 2019;139(7):1564–1573.e1568. doi:10.1016/j.jid.2019.01.014
   PubMed Web of Science ®Google Scholar
• Luan L, Ding Y, Han S, Zhang Z, Liu X. An increased proportion of circulating Th22 and Tc22 cells in psoriasis. Cell Immunol. 2014;290(2):196–200. doi:10.1016/j.cellimm.2014.06.007
   PubMed Web of Science ®Google Scholar
• Guilloteau K, Paris I, Pedretti N, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol. 2010;184(9):5263–5270. doi:10.4049/jimmunol.0902464
   PubMed Web of Science ®Google Scholar
• Pan Y, Du D, Wang L, Wang X, He G, Jiang X. The role of T helper 22 cells in dermatological disorders. Front Immunol. 2022;13:911546. doi:10.3389/fimmu.2022.911546
   PubMedGoogle Scholar
• Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–651. doi:10.1038/nature05505
   PubMed Web of Science ®Google Scholar
• Van Belle AB, de Heusch M, Lemaire MM, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol. 2012;188(1):462–469. doi:10.4049/jimmunol.1102224
   PubMed Web of Science ®Google Scholar
• Cheuk S, Wiken M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111–3120. doi:10.4049/jimmunol.1302313
   PubMed Web of Science ®Google Scholar
• Cai Y, Fleming C, Yan J. Dermal γδ T cells — a new player in the pathogenesis of psoriasis. Int Immunopharmacol. 2013;16(3):388–391. doi:10.1016/j.intimp.2013.02.018
   PubMed Web of Science ®Google Scholar
• Tomotaka M, Tomonori T, Hwang ST. Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol. 2011;187(10):5026–5031. doi:10.4049/jimmunol.1101817
   PubMed Web of Science ®Google Scholar
• Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity. 2009;31(2):321–330. doi:10.1016/j.immuni.2009.06.020
   PubMed Web of Science ®Google Scholar
• Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35(4):596–610. doi:10.1016/j.immuni.2011.08.001
   PubMed Web of Science ®Google Scholar
• Stanislav P, Stefan H, Barbara I, et al. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest. 2012;122(6):2252–2256. doi:10.1172/JCI61862
   PubMed Web of Science ®Google Scholar
• Ute L, Paola DM, Perera GK, et al. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol. 2011;187(5):2783–2793. doi:10.4049/jimmunol.1100804
   PubMed Web of Science ®Google Scholar
• Zhu R, Cai X, Zhou C, et al. Dermal Vγ(4)(+)T cells enhance the IMQ-induced psoriasis-like skin inflammatidon in re-challenged mice. Am J Transl Res. 2017;9(12):5347–5360.
   PubMed Web of Science ®Google Scholar
• Owczarczyk-Saczonek A, Czerwińska J, Placek W. The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27(1). doi:10.15570/actaapa.2018.4
   Web of Science ®Google Scholar
• Joseph B, Drew P, Fan P. Treg functional stability and its responsiveness to the microenvironment. Immunol Rev. 2014;259(1):115–139. doi:10.1111/imr.12172
   PubMed Web of Science ®Google Scholar
• Nedoszytko B, Lange M, Sokolowska-Wojdylo M, et al. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: the treg role in skin diseases pathogenesis. Postepy Dermatol Alergol. 2017;34(5):405–417. doi:10.5114/ada.2017.71105
   PubMed Web of Science ®Google Scholar
• Yun WJ, Lee DW, Chang SE, et al. Role of CD4+CD25high+FOXP3+ regulatory T cells in psoriasis. Ann Dermatol. 2010;22(4):397. doi:10.5021/ad.2010.22.4.397
   PubMed Web of Science ®Google Scholar
• Yan KX, Fang X, Han L, et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br J Dermatol. 2010;163(1):48–56. doi:10.1111/j.1365-2133.2010.09742.x
   PubMed Web of Science ®Google Scholar
• Li Z, Xue-Qin Y, Juan C, Rang-Song H, Tian-Wen G. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol. 2010;135(1):108–117. doi:10.1016/j.clim.2009.11.008
   PubMed Web of Science ®Google Scholar
• Fujimura T, Okuyama R, Ito Y, Aiba S. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol. 2010;158(6):1256–1263. doi:10.1111/j.1365-2133.2008.08504.x
   Web of Science ®Google Scholar
• Hideaki S, Rolland G, Eiko T, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174(1):164–173. doi:10.4049/jimmunol.174.1.164
   PubMed Web of Science ®Google Scholar
• Soler DC, Sugiyama H, Young AB, Massari JV, Mccormick TS, Cooper KD. Psoriasis patients exhibit impairment of the high potency CCR5 + T regulatory cell subset. Clin Immunol. 2013;149(1):111–118. doi:10.1016/j.clim.2013.06.007
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol. 2013;25(4):305–312. doi:10.1016/j.smim.2013.10.009
   PubMed Web of Science ®Google Scholar
• Jorn H, Kerkhof B, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131(9):1853–1860. doi:10.1038/jid.2011.139
   PubMed Web of Science ®Google Scholar
• Shao S, Cao T, Jin L, et al. Increased lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion. J Invest Dermatol. 2016;136(7):1418–1428. doi:10.1016/j.jid.2016.03.002
   PubMed Web of Science ®Google Scholar
• Polat M, Bugdayci G, Kaya H, Oğuzman H. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Turkish patients with chronic plaque psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(4):97–100. doi:10.15570/actaapa.2017.28
   PubMedGoogle Scholar
• Paliogiannis P, Satta R, Deligia G, et al. Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis. Clin Exp Med. 2019;19(1):37–45. doi:10.1007/s10238-018-0538-x
   PubMed Web of Science ®Google Scholar
• Balevi A, Olmuşçelik O, Ustuner P, Özdemir M. Is there any correlation between red cell distribution width, mean platelet volume neutrophil count, lymphocyte count, and psoriasis area severity index in patients under treatment for psoriasis? Acta Dermatovenerol Croat. 2018;26(3):199–205.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Matheson RT, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24(7):529–535. doi:10.1111/exd.12710
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32(1):227–255. doi:10.1146/annurev-immunol-032713-120225
   PubMed Web of Science ®Google Scholar
• Henry CM, Sullivan GP, Clancy DM, Afonina IS, Kulms D, Martin SJ. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016;14(4):708–722. doi:10.1016/j.celrep.2015.12.072
   PubMed Web of Science ®Google Scholar
• Weaver C, Hatton R, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25(1):821–852. doi:10.1146/annurev.immunol.25.022106.141557
   PubMedGoogle Scholar
• Lee KH, Kronbichler A, Park DD, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev. 2017;16(11):1160–1173. doi:10.1016/j.autrev.2017.09.012
   PubMed Web of Science ®Google Scholar
• Shao S, Fang H, Dang E, et al. Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4/IL-36R crosstalk. Front Immunol. 2019;10:746. doi:10.3389/fimmu.2019.00746
   PubMed Web of Science ®Google Scholar
• Hu SC, Yu HS, Yen FL, Lin CL, Chen GS, Lan CC. Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes. Sci Rep. 2016;6:31119.
   PubMed Web of Science ®Google Scholar
• Aubert P, Suarez-Farinas M, Mitsui H, et al. Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1beta. PLoS One. 2012;7(11):e49408. doi:10.1371/journal.pone.0049408
   PubMed Web of Science ®Google Scholar
• Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490–500. doi:10.4049/jimmunol.1100123
   PubMed Web of Science ®Google Scholar
• Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Front Immunol. 2012;3(Supplement):380. doi:10.3389/fimmu.2012.00380
   PubMedGoogle Scholar
• Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol. 2010;10(11):1325–1334. doi:10.1016/j.intimp.2010.08.012
   PubMed Web of Science ®Google Scholar
• Pinegin B, Vorobjeva N, Pinegin V. Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev. 2015;14(7):633–640. doi:10.1016/j.autrev.2015.03.002
   PubMed Web of Science ®Google Scholar
• Skrzeczynska-Moncznik J, Zabieglo K, Bossowski JP, et al. Eosinophils regulate interferon alpha production in plasmacytoid dendritic cells stimulated with components of neutrophil extracellular traps. J Interferon Cytokine Res. 2017;37(3):119–128. doi:10.1089/jir.2016.0036
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Ann Intern Med. 2018;168(7):Itc49–Itc64. doi:10.7326/AITC201804030
   PubMed Web of Science ®Google Scholar
• Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119. doi:10.1177/2040622318759282
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi:10.1007/s12016-018-8702-3
   PubMed Web of Science ®Google Scholar
• Di Domizio J, Gilliet M. Psoriasis caught in the NET. J Invest Dermatol. 2019;139(7):1426–1429. doi:10.1016/j.jid.2019.04.020
   PubMed Web of Science ®Google Scholar
• Tillack K, Breiden P, Martin R, Sospedra M. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol. 2012;188(7):3150–3159. doi:10.4049/jimmunol.1103414
   PubMed Web of Science ®Google Scholar
• Leite Dantas R, Masemann D, Schied T, et al. Macrophage-mediated psoriasis can be suppressed by regulatory T lymphocytes. J Pathol. 2016;240(3):366–377. doi:10.1002/path.4786
   PubMed Web of Science ®Google Scholar
• Morimura S, Oka T, Sugaya M, Sato S. CX3CR1 deficiency attenuates imiquimod-induced psoriasis-like skin inflammation with decreased M1 macrophages. J Dermatol Sci. 2016;82(3):175–188. doi:10.1016/j.jdermsci.2016.03.004
   PubMed Web of Science ®Google Scholar
• Hou Y, Zhu L, Tian H, et al. IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis. Protein Cell. 2018;9(12):1027–1038. doi:10.1007/s13238-018-0505-z
   PubMed Web of Science ®Google Scholar
• Nguyen CTH, Kambe N, Yamazaki F, Ueda-Hayakawa I, Kishimoto I, Okamoto H. Up-regulated expression of CD86 on circulating intermediate monocytes correlated with disease severity in psoriasis. J Dermatol Sci. 2018;90(2):135–143. doi:10.1016/j.jdermsci.2018.01.005
   PubMed Web of Science ®Google Scholar
• Lin SH, Chuang HY, Ho JC, Lee CH, Hsiao CC. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation. J Dermatol Sci. 2018;91(3):276–284. doi:10.1016/j.jdermsci.2018.05.009
   PubMed Web of Science ®Google Scholar
• Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007;48(2):87–101. doi:10.1016/j.jdermsci.2007.06.006
   PubMed Web of Science ®Google Scholar
• Koh MS, Majewski BB, Rhodes EL. Increased macrophage activity in psoriasis. Acta Derm Venereol. 1985;65(3):194–198. doi:10.2340/0001555565194198
   PubMed Web of Science ®Google Scholar
• Das A, Sinha M, Datta S, et al. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol. 2015;185(10):2596–2606. doi:10.1016/j.ajpath.2015.06.001
   PubMed Web of Science ®Google Scholar
• Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44(3):450–462. doi:10.1016/j.immuni.2016.02.015
   PubMed Web of Science ®Google Scholar
• Vannella KM, Wynn TA. Mechanisms of organ injury and repair by macrophages. Annu Rev Physiol. 2017;79(1):593–617. doi:10.1146/annurev-physiol-022516-034356
   PubMedGoogle Scholar
• Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7(1):385–422. doi:10.1146/annurev-pathol-011811-132448
   PubMed Web of Science ®Google Scholar
• Schultze JL, Schmieder A, Goerdt S. Macrophage activation in human diseases. Semin Immunol. 2015;27(4):249–256. doi:10.1016/j.smim.2015.07.003
   PubMed Web of Science ®Google Scholar
• Judilyn FD, Mayte SFA, Zaba LC, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010;130(10):2412. doi:10.1038/jid.2010.165
   PubMed Web of Science ®Google Scholar
• Lorthois I, Asselineau D, Seyler N, Pouliot R. Contribution of in vivo and organotypic 3D models to understanding the role of macrophages and neutrophils in the pathogenesis of psoriasis. Mediators Inflamm. 2017;2017:7215072. doi:10.1155/2017/7215072
   PubMed Web of Science ®Google Scholar
• Mantsounga CS, Lee C, Neverson J, et al. Macrophage IL-1β promotes arteriogenesis by autocrine STAT3- and NF-κB-mediated transcription of pro-angiogenic VEGF-A. Cell Rep. 2022;38(5):110309.
   PubMed Web of Science ®Google Scholar
• Ataseven A, Temiz SA, Eren G, Özer İ, Dursun R. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat. 2022;33(2):1091–1096. doi:10.1080/09546634.2020.1801975
   PubMed Web of Science ®Google Scholar